BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction
ConditionLung Transplant Recipient
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorNorthwestern University
About this trial
This study will determine if primary graft dysfunction (which causes low blood oxygen levels and fluid or inflammation in the lungs) after lung transplant can be prevented through the use of the study drug (IL-1 receptor antagonist, Anakinra). In this study, lung transplant participants who are randomized to the treatment group will have the study drug injected into the solution that their donor lungs are kept in prior to transplant.
Eligibility criteria
Qualifiers
Age 18 years or older.
Planning to undergo transplantation of the lung.
Willing and able to read, understand, and be capable of giving informed consent.
Use of ex vivo lung perfusion (EVLP) prior to lung transplant.
Disqualifiers
Previous or current use of IL-1R antagonist drug.
Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating, such as highly sensitized patients who require additional immunosuppression, multiorgan transplant, and re- transplant.
Trial design
Treatments tested in this trial
- Anakinra
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov